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L E T T E R  T O  T H E  E D I T O R
Coexisting pituitary and non‐pituitary gigantism in the 
same family
Germline aryl hydrocarbon receptor‐interacting protein (AIP) muta‐
tions are present in 15%‐30% of familial isolated pituitary adenoma 
(FIPA)	 families,	 and	are	 responsible	 for	30%	of	pituitary	gigantism	
cases.1	However,	pathological	accelerated	growth	and/or	tall	stature	
can	be	unrelated	to	the	growth	hormone	(GH)	axis,	and	may	occur	in	
isolation	or	as	part	of	a	syndrome,	such	as	in	Klinefelter,	Marfan	or	
Sotos syndromes.2	Here,	we	report	a	five‐generation	kindred	with	
two brothers with pituitary gigantism due to AIP mutation‐positive 
GH‐secreting pituitary adenomas and their first‐cousin coincidently 
also	having	gigantism	due	to	Marfan	syndrome	(Figure	1).
The	 proband,	 exhibited	 accelerated	 linear	 growth	 since	 he	
was	 8	years‐old,	 and	 at	 the	 age	 of	 10	 measured	 153	cm	 (height	
SDS + 2.1). He was diagnosed with pituitary gigantism due to a 
2.5 cm GH‐secreting pituitary adenoma. Following transsphenoidal 
surgery,	 cabergoline	 and	 octreotide	 LAR	were	 ineffective,	 and	 he	
was then successfully treated with pegvisomant3; his final height is 
200 cm. His brother presented a few years later at the age of 16 with 
accelerated	growth	 (height	=	201	cm,	SDS	+	3.9),	and	he	was	oper‐
ated on two occasions for a somatolactotropinoma. His final height 
is 209.5 cm.
Genetic testing identified a truncating heterozygous nonsense 
mutation in the AIP gene	 (c.910C>T;	 p.R304*)	 in	 both	 patients,	 as	
well	as	in	eight	unaffected	family	members,	who	are	currently	under	
surveillance.	 A	 deceased	 uncle	 had	 acromegaly	 based	 on	 photo‐
graphs.	In	the	same	kindred	there	is	a	tall	first‐cousin	(height	208	cm)	
due	to	Marfan	syndrome	(Figure	1).
This is a unique family where two different diseases cause gigantism 
in close family members. The clinical diagnosis of the two brothers af‐
fected with GH‐related pituitary gigantism may have been hindered by 
the	presence	of	extreme	tall	stature	in	this	family	due	to	Marfan	syn‐
drome. Clinical and biochemical exclusion of GH‐related pituitary gigan‐
tism	is	usually	straightforward.	However,	the	evaluation	and	management	
of patients with tall stature and/or acromegaloid features without GH/
IGF‐1	 axis	 abnormalities,	 i.e.	 pseudoacromegaly,	 may	 be	 challenging,	
particularly when the classical features of the underlying overgrowth 
syndrome	are	absent,	there	are	coexistent	acromegaloid	features,	bio‐
chemical	discrepancies	in	the	GH	axis	assessment,	or	family	history	of	
pituitary adenomas as illustrated here and elsewhere.4 Incidentally de‐
tected pituitary adenomas in these patients may further complicate the 
establishment of the correct underlying diagnosis.4 Overlapping features 
between GH excess and other conditions can present challenging issues 
for patients and their families as well as for their physicians.4,5
Marfan	syndrome	is	an	autosomal	dominant	disorder	caused	by	
loss‐of‐function variants in the FBN1 gene,	mainly	affecting	the	skel‐
etal,	ocular	and	cardiovascular	systems.	In	Marfan	syndrome,	exces‐
sive linear growth of long bones starting at an early age results in tall 
stature,	which	 justifies	 the	assessment	of	GH	axis.	However,	other	
typical	manifestations	such	as	joint	laxity,	long	fingers,	disproportion‐
ate	long	extremities	for	trunk	size	with	increased	arm	span‐to‐height	
and	lower‐to‐upper	segment	ratios,	pectus	carinatum	or	excavatum,	
as	well	as	other	features	(myopia,	ectopia	lens,	cardiovascular	anoma‐
lies)	should	lead	to	an	accurate	diagnosis	of	Marfan	syndrome.2
The diagnosis of many of the pseudoacromegaly conditions are 
usually established by experienced geneticists or dedicated paedia‐
tricians,	but	some	of	the	conditions	may	be	referred	first	to	endocri‐
nologists for investigation of possible GH excess or other hormonal 
disturbances	affecting	growth,	such	as	precocious	puberty,	hypogo‐
nadism or thyrotoxicosis.2,5	 Therefore,	 endocrinologists	 should	 be	
aware of conditions masquerading as acromegaly/pituitary gigantism 
and thus be able to aid in establishing the underlying diagnosis.4,5
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F I G U R E  1   Pituitary gigantism due to AIP	mutation‐positive	pituitary	adenomas	in	two	brothers	(IV.c,	196	cm;	IV.d,	201	cm	at	the	time	
of	the	photograph)	and	non‐pituitary	gigantism	due	to	Marfan	syndrome	in	their	first‐cousin	(IV.h,	208	cm)	[Colour	figure	can	be	viewed	at	
wileyonlinelibrary.com]
